Invest for a Sustainable Future, Impact Capital Asset Management

ICAM

Established in August 2020, Impact Capital Asset Management Pte. Ltd. (ICAM) was conceived by seasoned professionals Deepak Mawandia and Atul Tetambe. Both have accumulated a wealth of knowledge and experience from their extensive tenures in the financial sector. In 2019, ICAM secured its RFMC license and subsequently introduced a technology-centric venture fund. By 2021, with the acquisition of its CMS license, ICAM witnessed steady growth in its assets under management.

Presently, ICAM manages a portfolio exceeding USD 1 billion, diversified across various countries. Central to ICAM’s foundation is a commitment to offering a platform singularly dedicated to the best interests of its investor clients. The combined expertise of Deepak and Atul firmly establishes ICAM as a notable entity in the wealth management field.

Invest for a Sustainable Future

Impact Capital Asset Management

Established in August 2020, Impact Capital Asset Management Pte. Ltd. (ICAM) was conceived by seasoned professionals Deepak Mawandia and Atul Tetambe. Both have accumulated a wealth of knowledge and experience from their extensive tenures in the financial sector. In 2019, ICAM secured its RFMC license and subsequently introduced a technology-centric venture fund. By 2021, with the acquisition of its CMS license, ICAM witnessed steady growth in its assets under management. Presently, ICAM manages a portfolio exceeding USD 1 billion, diversified across various countries. Central to ICAM’s foundation is a commitment to offering a platform singularly dedicated to the best interests of its investor clients. The combined expertise of Deepak and Atul firmly establishes ICAM as a notable entity in the wealth management field.

Equity Bottom-Up

<ul><li>UltraGreen is best understood as a fluorescence-guided surgery company whose current earnings base sits in indocyanine green, or ICG, sold as IC-GREEN in the US and Verdye outside North America.</li><li>The company has built that franchise through regulatory approvals, distribution reach, supply-chain control and surgeon adoption rather than through software monetization.</li><li>The right first-order framing is a high-margin consumables business with medtech workflow support, not a software platform first. </li></ul>

UltraGreen is best understood as a fluorescence-guided surgery company whose current earnings base sits in indocyanine green, or ICG, sold as IC-GREEN in the US and Verdye outside North America.The company has built that franchise through regulatory approvals, distribution reach, supply-chain control and surgeon adoption rather than through software monetization.The right first-order framing is a high-margin consumables business with medtech workflow support, not a software platform first. 

UltraGreen.ai Limited: Initiating Coverage Report